Dose‐dependent inactivation of airway tryptase with a novel dissociating anti‐tryptase antibody (MTPS9579A) in healthy participants: A randomized trial
Authors:
Open Access
- 27 September 2021
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 15 (2) , 451-463
Abstract
Tryptase is the most abundant secretory granule protein in human lung mast cells and plays an important role in asthma pathogenesis. MTPS9579A is a novel monoclonal antibody that selectively inhibits tryptase activity by dissociating active tetramers into inactive monomers. The safety, tolerability, pharmacokinetics (PKs), and systemic and airway pharmacodynamics (PDs) of MTPS9579A were assessed in healthy participants. In this phase I single‐center, randomized, observer‐blinded, and placebo‐controlled study, single and multiple ascending doses of MTPS9579A were administered subcutaneously (s.c.) or intravenously (i.v.) in healthy participants. In addition to monitoring safety and tolerability, the concentrations of MTPS9579A, total tryptase, and active tryptase were quantified. This study included 106 healthy participants (82 on active treatment). Overall, MTPS9579A was well‐tolerated with no serious or severe adverse events. Serum MTPS9579A showed a dose‐proportional increase in maximum serum concentration (Cmax) values at high doses, and a nonlinear increase in area under the curve (AUC) values at low concentrations consistent with target‐mediated clearance were observed. Rapid and dose‐dependent reduction in nasosorption active tryptase was observed postdose, confirming activity and the PK/PD relationship of MTPS9579A in the airway. A novel biomarker assay was used to demonstrate for the first time that an investigative antibody therapeutic (MTPS9579A) can inhibit tryptase activity in the upper airway. A favorable safety and tolerability profile supports further assessment of MTPS9579A in asthma. Understanding the exposure‐response relationships using the novel PD biomarker will help inform clinical development, such as dose selection or defining patient subgroups.Keywords
Funding Information
- Genentech
This publication has 20 references indexed in Scilit:
- Assessment and Reporting of the Clinical Immunogenicity of Therapeutic Proteins and Peptides—Harmonized Terminology and Tactical RecommendationsThe AAPS Journal, 2014
- Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematologyEuropean Journal of Clinical Investigation, 2009
- Biology of mast cell tryptaseThe FEBS Journal, 2006
- Structural Requirements and Mechanism for Heparin-dependent Activation and Tetramerization of Human βI- and βII-TryptaseJournal of Molecular Biology, 2005
- Tryptase: potential role in airway inflammation and remodelingAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2002
- Mast Cell Tryptases and Airway RemodelingAmerican Journal of Respiratory and Critical Care Medicine, 2001
- Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthmaJournal of Allergy and Clinical Immunology, 2001
- Tryptase Inhibition2001
- Inhibition of allergen-induced pulmonary responses by the selective tryptase inhibitor 1,5-bis-{4-[(3-carbamimidoyl-benzenesulfonylamino)-methyl]-phenoxy}-pentane (AMG-126737)Biochemical Pharmacology, 1999
- Pharmacologic target-mediated drug dispositionClinical Pharmacology & Therapeutics, 1994